Dr. Carpenter’s career experience includes providing primary care to underserved populations, performing clinical and basic science research, and leadership positions in academic medicine, pharmaceutical, and biotechnology companies. Most recently, he founded Seaside Therapeutics to leverage breakthrough scientific discoveries and develop therapeutics capable of correcting molecular perturbations that increase vulnerability to intellectual disability and autism. The experiences and knowledge gained establishing collaborations with expert clinicians, academic medical centers, scientists, patient advocacy groups, NIH, and biopharmaceutical companies are directly relevant to his role at RSRT and provide insights for effectively leveraging the expertise of a wide range of stakeholders.
He also authored and served as principal investigator on UO1 translational medicine grants jointly funded by NIMH, NINDS, NICHD, Autism Speaks, and FRAXA, helped establish a fragile X clinical trial network, participated in NIH/FDA workgroups, and directly engaged FDA to define regulatory requirements for development of drugs to treat fragile X syndrome. He continues to be engaged in parallel and complementary efforts through participation in the advisory boards of EU-AIMS and the Translational Neuroscience Center of Boston Children’s Hospital, and as a research affiliate in the Department of Brain and Cognitive Sciences at MIT.
While in industry, he led translational medicine teams responsible for eight successful IND submissions and dozens of FDA-compliant clinical trials. Prior to joining industry, he held academic faculty appointments at Virginia Mason Medical Center, the University of Washington, and Wake Forest University, where he specialized in anesthesiology, pain management, and translational medicine.